Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 3, 2012, Pages 387-394

  Imahashi, N ^a   Inamoto, Y ^a   Ito, M ^a   Koyama, D ^a   Goto, T ^a   Onodera, K ^a   Seto, A ^a   Watanabe, K ^a   Imahashi, M ^a   Nishiwaki, S ^a   Tsukamoto, S ^a   Yasuda, T ^a   Ozawa, Y ^a   Miyamura, K ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

hemophagocytosis; macrophages; non relapse mortality; SCT

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW EXAMINATION; CAUSE OF DEATH; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENGRAFTMENT SYNDROME; ERYTHROPHAGOCYTOSIS; FEMALE; GRAFT FAILURE; HEMATOLOGIC DISEASE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; THERAPY EFFECT;

EID: 85028115490     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.95     Document Type: Article

References (36)

1. Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357: 1777-1789. (Pubitemid 32524226)
2. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008; 112: 935-945.
3. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
4. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598. (Pubitemid 36529900)
5. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898. (Pubitemid 32529870)
6. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016. (Pubitemid 20067204)
7. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150-1156. (Pubitemid 36722247)
8. Abe Y, Choi I, Hara K, Matsushima T, Nishimura J, Inaba S et al. Hemophagocytic syndrome: a rare complication of allogeneic nonmyeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 799-801. (Pubitemid 34618914)
9. Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009; 114: 3113-3116.
10. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-481. (Pubitemid 35303816)
11. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
12. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111(2 Suppl): S460-S475.
13. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206. (Pubitemid 35332066)
14. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008; 14: 859-866. (Pubitemid 351985024)
15. Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant 2005; 11: 542-550. (Pubitemid 40862451)
16. Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2008; 14: 438-444. (Pubitemid 351372749)
17. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
18. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
21. Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143-1150. (Pubitemid 38786505)
22. Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009; 44: 43-49.
23. Woywodt A, Haubitz M, Buchholz S, Hertenstein B. Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 1015-1023. (Pubitemid 40028832)
24. Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991; 8: 393-401.
25. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500. (Pubitemid 26067737)
26. Parker AN, Pragnell IB. Inhibitors of haemopoiesis and their potential clinical relevance. Blood Rev 1995; 9: 226-233. (Pubitemid 26038502)
27. Janka GE. Hemophagocytic syndromes. Blood Rev 2007; 21: 245-253. (Pubitemid 47212601)
28. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654. (Pubitemid 38970556)
29. Koyama M, Sawada A, Yasui M, Inoue M, Kawa K. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol 2007; 86: 466-467.
30. Frankenberger M, Haussinger K, Ziegler-Heitbrock L. Liposomal methylprednisolone differentially regulates the expression of TNF and IL-10 in human alveolar macrophages. Int Immunopharmacol 2005; 5: 289-299. (Pubitemid 40126355)
31. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002; 79: 29-40. (Pubitemid 34164159)
32. Thiele J, Kvasnicka HM, Beelen DW, Wenzel P, Koepke ML, Leder LD et al. Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia. Virchows Arch 2000; 437: 160-166. (Pubitemid 30623575)
33. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004; 122: 794-801. (Pubitemid 39434761)
34. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006; 148: 683-686. (Pubitemid 43776910)
35. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22: 561-566.
36. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47: 1650-1660.